Clinical trial
Long-Term Lamivudine Therapy for Chronic Hepatitis B
NCT00120354 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH · Completed
Key facts
| NCT number | NCT00120354 |
|---|---|
| Title | Long-Term Lamivudine Therapy for Chronic Hepatitis B |
| Official title | Long-Term Lamivudine Therapy for Chronic Hepatitis B |
| Lead sponsor | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Chronic |
| Intervention type | Procedure |
| Interventions | Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy |
| Enrollment | 50 |
| Start date | Jul 11, 2005 |
| Completion | Mar 31, 2007 |
| First posted | Jul 15, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: